Second-Line Antiretroviral Treatment Outcome in HIV-Infected Patients Coinfected with Tuberculosis in Pakistan

Table 3

Clinico-immunological and virological outcome in HIV-/TB-coinfected patients on 2^nd-line ART, coadministered with or without ATT.

S. No.	Characteristic/risk factor	Total patient No. (%)	HIV^yesTB^yes patient on ATT No. (%)	HIV^yesTB^no patient not on ATT No. (%)	value
1	Adherence to 2^nd-line ART
	<95%	6 (18.2%)	3 (50.0%)	3 (50.0%)	—
	≥95%	27 (81.8%)	10 (37.0%)	17 (63.0%)	0.000
2	NRTI combination 2^nd-line regimen initiated
	Tenofavir based	22 (66.7%)	9 (40.9%)	13 (59.1%)	—
	Non-Tenofavir based	11 (33.3%)	4 (36.4%)	7 (63.6%)	0.801
3	ARV side effect during 2^nd-line ART
		8	7	1	0.000
4	ARV switching during 2^nd-line ART
		7 (21.2%)	3 (42.9%)	4 (57.1%)	0.833
5	Clinical outcome
	Death	6 (18.2%)	3 (50.0%)	3 (50.0%)	—
	LTFU	1 (3.0%)	1 (100%)	0	—
	Alive	26 (78.8%)	9 (34.6%)	17 (65.4%)	0.355
6	Virological failure while on 2^nd-line ART
		13 (39.4%)	9 (69.2%)	4 (30.8%)	0.005
7	CD4 at 12 months of 2^nd line (cells/mm^3)
	<200	6 (18.2%)	3 (50.0%)	3 (50.0%)	—
	≥200	27 (81.8%)	10 (37.0%)	17 (63.0%)	0.557
8	CD4 gain after 2^nd-line ART of 12 months (cells/mm^3)
	<100	7 (21.2%)	4 (57.1%)	3 (42.9%)	—
	≥100	26 (78.8%)	9 (34.6%)	17 (65.4%)	0.279
9	VL after 2^nd-line ART of 12 months (copies/ml)
	<1000	23 (69.7%)	4 (17.4%)	19 (82.6%)
	≥1000	10 (30.3%)	9 (90.0%)	1 (10.0%)	0.000

NRTI: nucleoside reverse transcriptase inhibitors; ARV: antiretroviral; LTFU: loss to follow-up.